IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentees: Kazunnari Nakao, et al. Examiner:

Examiner: Laura Lynne Stockton

Patent No: 6,710,054

Art Unit: 1626

Issued:

March 23, 2004

Docket:

23179 (FP1126-US)

For:

ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS

ANTI-INFLAMMATORY AND ANALGESIC AGENTS

Confirmation No.: 2547

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> REVOCATION OF PRIOR POWERS AND APPOINTMENT OF NEW ATTORNEYS CHANGE OF CORRESPONDENCE ADDRESS AND CERTIFICATE UNDER 37 C.F.R. §3.73(b)

I hereby certify that RaQualia Pharma Inc. is the assignee of the entire right, title and interest in the patent application identified above.

Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjo and Kana Taniguchi inventors of the above-identified application have transferred their right, title and interest in and to the subject matter of the above-identified application by Assignment dated July 9, 2001 to Pfizer Pharmaceuticals Inc. The Assignment was recorded on April 7, 2003 in the United States Patent and Trademark Office under Reel 013568 and Frame 0805. Pfizer Pharmaceuticals Inc. assignee of the above-identified application have transferred their right, title and interest in and to the subject matter of the above-identified application by Assignment dated July 11, 2001 to Pfizer Inc. The Assignment was recorded on April 7, 2003 in the United States Patent and Trademark Office under Reel 013568 and Frame 0796. Pfizer Inc. assignor of the above-identified application

have transferred their right, title and interest in and to the subject matter of the above-identified application by Assignment dated July 25, 2008 to RaQualia Pharma Inc. The Assignment was recorded on September 4, 2008 in the United States Patent and Trademark Office under Reel 021478 and Frame 0104.

I have reviewed the Assignment document of the patent application identified above and, to the best of my knowledge and belief, RaQualia Pharma Inc. has title in and to the above-identified application.

I hereby revoke all previous Powers of Attorney in the above-identified case and I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

CUSTOMER NO. 00272

Address all telephone calls to Peter I. Bernstein at telephone no. 516-742-4343.

Address all correspondence to Peter I. Bernstein, Scully, Scott, Murphy & Presser, P.C., 400 Garden City Plaza, Suite 300, Garden City, New York 11530.

The undersigned is authorized to sign this certificate on behalf of the assignee.

10/24/08